Skip to main content
SpringerLink
Log in

Structure-guided drug discovery: back to the future

  • Comment
  • Published:

From Nature Structural & Molecular Biology

View current issue Submit your manuscript

Over the past 30 years, the field of structural biology and its associated biological insights have seen amazing progress. In this Comment, I recount several milestones in the field and how we can apply lessons from the past toward an exciting future, especially as it relates to drug discovery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Frye, S. Nat. Chem. Biol. 6, 159–161 (2010).

    Article  CAS  PubMed  Google Scholar 

  2. Arrowsmith, C. et al. Nat. Chem. Biol. 11, 536–541 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Edwards, A. et al. Nature 470, 163–165 (2011).

    Article  ADS  CAS  PubMed  Google Scholar 

  4. Carter, A. J. et al. Drug Discov. Today 26, 607–612 (2019).

    Google Scholar 

  5. Jumper, J. et al. Nature 596, 583–589 (2021).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  6. Baek, M. et al. Science 373, 871–876 (2021).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kryshtafovych, A., Schwede, T., Topf, M., Fidelis, K. & Moult, J. Proteins 91, 1539–1549 (2020).

    Article  Google Scholar 

  8. Nature 617, 438 (2023).

  9. Ackloo, S. et al. Nat. Rev. Chem. 6, 287–295 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

C.H.A. is funded by the Canadian Institutes for Health Research (FDN154328 and OGB190363), Canada foundation for Innovation, National Institutes of Health (U19 AI171292), Huntington Society of Canada, Princess Margaret Cancer Centre, The Princess Margaret Cancer Foundation, and Ontario Ministry of Health. The Structural Genomics Consortium is a registered charity (no. 1097737) that receives funds from Bayer AG, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Genome Canada through Ontario Genomics Institute (OGI-196), EU/EFPIA/OICR/McGill/KTH/Diamond Innovative Medicines Initiative 2 Joint Undertaking (EUbOPEN grant 875510), Janssen, Merck (known as EMD in Canada and the United States), Pfizer and Takeda.

Author information

Authors and Affiliations

  1. Princess Margaret Cancer Centre, Toronto, Ontario, Canada

    Cheryl H. Arrowsmith

  2. Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada

    Cheryl H. Arrowsmith

  3. Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

    Cheryl H. Arrowsmith

Authors
  1. Cheryl H. Arrowsmith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cheryl H. Arrowsmith.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Arrowsmith, C.H. Structure-guided drug discovery: back to the future. Nat Struct Mol Biol 31, 395–396 (2024). https://doi.org/10.1038/s41594-024-01244-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41594-024-01244-3

  • Springer Nature America, Inc.

Search

Navigation